For most people at higher risk of severe COVID-19, Paxlovid is worth taking. In a large CDC study of nearly 700,000 U.S. adults during 2022, those who took Paxlovid within five days of their diagnosis were 51% less likely to be hospitalized in the following month. The benefit held up in vaccinated people and those who’d had prior infections. But whether it makes sense for you depends on your risk level, what medications you take, and how quickly you can start treatment.
How Much It Reduces Hospitalization and Death
The original clinical trial, conducted in unvaccinated people before the Omicron variant, showed an 89% reduction in severe outcomes. That number dropped once real-world conditions changed. Among a mix of vaccinated and unvaccinated adults in the U.S. during 2022, the hospitalization rate within 30 days was 0.47% for Paxlovid recipients compared to 0.86% for those who didn’t take it. The death rate was also lower: 0.01% versus 0.04%.
Those percentages look small in absolute terms, and that’s actually the key tension behind the “is it worth it” question. For any individual, the baseline risk of being hospitalized with COVID-19 is already low, especially if you’re vaccinated. But for people with conditions that raise their risk, cutting that already-modest number roughly in half is meaningful. The drug works by blocking the virus from copying itself, so it shortens the window during which the infection can escalate.
Who Benefits Most
You’re eligible for Paxlovid if you’re 50 or older, or if you have a condition that puts you at higher risk for severe illness. The CDC’s list of qualifying conditions is broader than many people realize. It includes diabetes, obesity (a BMI of 25 or higher), heart disease, chronic kidney disease at any stage, moderate-to-severe asthma, COPD, cancer, pregnancy, depression, schizophrenia spectrum disorders, HIV, immunocompromised status, and even physical inactivity.
Interestingly, the drug appears to work slightly better in vaccinated people than in unvaccinated ones. One large study using electronic health records found a 42% relative risk reduction in hospitalization for vaccinated patients, compared to 26% for unvaccinated patients. This may seem counterintuitive, but vaccination primes the immune system in ways that complement what Paxlovid does on the viral side.
The Five-Day Treatment Window
Paxlovid must be started within five days of your first symptoms. This is the single most important practical detail. The drug is taken twice daily for five days, and every hour of delay chips away at its effectiveness. If you wake up with a sore throat and test positive on a Tuesday, you need a prescription filled and in hand quickly, not by the weekend. Many people miss their window simply because they wait to see if symptoms worsen before seeking treatment, or because they can’t get a telehealth or in-person appointment fast enough.
Side Effects Are Real but Manageable
The most common complaint is a metallic or bitter taste in the mouth, reported by roughly 18% of people in post-marketing data. Some describe it as persistently unpleasant for the full five days of treatment. Diarrhea and nausea also occur. These side effects are annoying but temporary, and for most people they resolve once the course is finished. Serious adverse reactions are rare.
Drug Interactions Are the Biggest Obstacle
One of the two active components in Paxlovid (ritonavir) interferes with the same liver enzyme that processes roughly 60% of common medications. This creates a long list of drugs that cannot be taken alongside Paxlovid, and this is the most common reason a doctor might steer you away from it.
The contraindicated medications span several categories:
- Heart medications: amiodarone, flecainide, dronedarone, ranolazine, propafenone
- Blood thinners: rivaroxaban
- Cholesterol drugs: simvastatin, lovastatin
- Seizure medications: carbamazepine, phenobarbital, phenytoin
- Certain psychiatric medications: clozapine, quetiapine, lurasidone, pimozide
- Some sedatives: oral midazolam, triazolam, diazepam
- Colchicine (used for gout)
- St. John’s wort
If you take any of these, Paxlovid is typically off the table. For some medications, a doctor may temporarily pause or adjust the dose, but that depends on the specific drug and your health situation. Having a current medication list ready when you call about a COVID-19 prescription saves valuable time during that five-day window.
What About Rebound?
COVID rebound, where symptoms or a positive test return a few days after finishing the medication, got a lot of attention early on. The clinical trial data tells a more nuanced story. In the original trials, viral rebound (meaning detectable virus levels climbing again after treatment) occurred in about 6% to 8% of people who took Paxlovid. But it also occurred in about 6% to 7% of people who took a placebo. The difference between those numbers was not statistically significant in most analyses.
In other words, rebound appears to be largely a feature of COVID-19 itself, not something Paxlovid uniquely causes. The drug may make rebound more noticeable because people feel better faster and then notice a return of symptoms, while someone who never took the drug might experience a more gradual, bumpy recovery without labeling it “rebound.”
Does It Prevent Long COVID?
This is where the picture is less encouraging. A large analysis from the RECOVER trial found that Paxlovid had no overall protective effect against long COVID. There was a modest signal in older adults: people 65 and older saw a 12% reduced risk of developing at least one long-COVID symptom. Younger adults between 18 and 49 had a smaller 7% reduction. But even in the best-case group, 233 people would need to be treated to prevent a single case. If preventing long COVID is your primary motivation, Paxlovid alone is unlikely to be a reliable shield.
Cost and Access
Paxlovid is no longer free through the federal government’s pandemic supply. It is now a commercially available prescription, which means your out-of-pocket cost depends on your insurance. Pfizer runs a patient assistance program called PAXCESS that offers co-pay savings of up to $1,500 per prescription for commercially insured patients, potentially bringing the cost to $0 or $25 at participating pharmacies. For patients on Medicare, Medicaid, TRICARE, or those who are uninsured, Pfizer had been providing the drug at no cost, though the specifics of these programs can change year to year. Checking the PAXCESS program or calling your pharmacy before you need it is the practical move, since you won’t want to be sorting out insurance questions while your treatment window is ticking down.
The Bottom Line on Value
Paxlovid’s clearest benefit is for people over 50 or those with qualifying health conditions who can start the drug within five days of symptoms. It cuts hospitalization risk roughly in half, has tolerable side effects, and finishes in five days. It does not reliably prevent long COVID, and it won’t work if you can’t start it in time or if your medications conflict with it. For a healthy 30-year-old with no risk factors, the absolute benefit is small because the baseline risk is already low. For a 65-year-old with diabetes and heart disease, halving an already elevated risk is a straightforward win.